'Covid is not going away': Virologist fund manager Dr Ogden on coronavirus, healthcare valuations and biotech opportunities

Single vaccine 'not enough' to treat patients

Lauren Mason
clock • 7 min read
Platinum Asset Management's Dr Bianca Ogden

Platinum Asset Management's Dr Bianca Ogden

The coronavirus pandemic has changed how the world's healthcare systems and biotechnology companies will operate irrevocably as Covid-19 "isn’t going to go away", according to virologist and manager of the AUS$335m Platinum International Healthcare fund Dr Bianca Ogden.

Ogden, who obtained a PhD in virology, and previously worked as a scientist for Johnson & Johnson and Novartis before launching the portfolio in 2003, said comparisons can be made between the Covid-19...

To continue reading this article...

Join Investment week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now


Already an Investment Week


More on Markets

Luke Hickmore, investment director fixed income, abrdn

Jubilee economics - how does 1952 compare to 2022?

Some similarities

Luke Hickmore
clock 24 May 2022 • 4 min read
Market Movers Blog: US inflation dips slightly to 8.3%

Market Movers Blog: UK Government borrowing reaches historic high in April

Latest news and analysis

Investment Week
clock 24 May 2022 • 1 min read
Industry Voice: Not All Currencies Are Made Equal, So Don't Treat Them as Such

Industry Voice: Not All Currencies Are Made Equal, So Don't Treat Them as Such

Selective currency hedging may boost yields and add stability

Michael Walsh, Multi‑Asset Solutions Strategist at T. Rowe Price
clock 20 May 2022 • 3 min read